South Korea · Delayed Price · Currency is KRW Whan In Pharm Statistics
Total Valuation
Whan In Pharm has a market cap or net worth of KRW 192.05 billion. The enterprise value is 129.01 billion.
| Market Cap | 192.05B |
| Enterprise Value | 129.01B |
Important Dates
The next estimated earnings date is Thursday, April 30, 2026.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Whan In Pharm has 18.48 million shares outstanding. The number of shares has increased by 3.86% in one year.
| Current Share Class | 18.48M |
| Shares Outstanding | 18.48M |
| Shares Change (YoY) | +3.86% |
| Shares Change (QoQ) | +3.08% |
| Owned by Insiders (%) | 23.42% |
| Owned by Institutions (%) | 12.44% |
| Float | 14.15M |
Valuation Ratios
The trailing PE ratio is 12.12 and the forward PE ratio is 10.70.
| PE Ratio | 12.12 |
| Forward PE | 10.70 |
| PS Ratio | 0.75 |
| PB Ratio | 0.46 |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | 31.01 |
| P/OCF Ratio | 21.24 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.69, with an EV/FCF ratio of 20.83.
| EV / Earnings | 9.49 |
| EV / Sales | 0.51 |
| EV / EBITDA | 5.69 |
| EV / EBIT | 10.06 |
| EV / FCF | 20.83 |
Financial Position
The company has a current ratio of 4.04, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.04 |
| Quick Ratio | 2.30 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | 0.11 |
| Interest Coverage | 452.49 |
Financial Efficiency
Return on equity (ROE) is 3.41% and return on invested capital (ROIC) is 3.42%.
| Return on Equity (ROE) | 3.41% |
| Return on Assets (ROA) | 1.80% |
| Return on Invested Capital (ROIC) | 3.42% |
| Return on Capital Employed (ROCE) | 3.08% |
| Weighted Average Cost of Capital (WACC) | 4.95% |
| Revenue Per Employee | 424.65M |
| Profits Per Employee | 22.62M |
| Employee Count | 601 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 2.00 |
Taxes
In the past 12 months, Whan In Pharm has paid 1.33 billion in taxes.
| Income Tax | 1.33B |
| Effective Tax Rate | 8.92% |
Stock Price Statistics
The stock price has decreased by -6.98% in the last 52 weeks. The beta is 0.13, so Whan In Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -6.98% |
| 50-Day Moving Average | 10,535.60 |
| 200-Day Moving Average | 11,237.40 |
| Relative Strength Index (RSI) | 49.09 |
| Average Volume (20 Days) | 27,032 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Whan In Pharm had revenue of KRW 255.21 billion and earned 13.60 billion in profits. Earnings per share was 857.41.
| Revenue | 255.21B |
| Gross Profit | 86.40B |
| Operating Income | 13.02B |
| Pretax Income | 14.93B |
| Net Income | 13.60B |
| EBITDA | 22.88B |
| EBIT | 13.02B |
| Earnings Per Share (EPS) | 857.41 |
Balance Sheet
The company has 63.72 billion in cash and 679.00 million in debt, with a net cash position of 63.04 billion or 3,410.59 per share.
| Cash & Cash Equivalents | 63.72B |
| Total Debt | 679.00M |
| Net Cash | 63.04B |
| Net Cash Per Share | 3,410.59 |
| Equity (Book Value) | 421.01B |
| Book Value Per Share | 22,776.90 |
| Working Capital | 171.77B |
Cash Flow
In the last 12 months, operating cash flow was 9.04 billion and capital expenditures -2.85 billion, giving a free cash flow of 6.19 billion.
| Operating Cash Flow | 9.04B |
| Capital Expenditures | -2.85B |
| Depreciation & Amortization | 9.86B |
| Net Borrowing | -539.92M |
| Free Cash Flow | 6.19B |
| FCF Per Share | 335.08 |
Margins
Gross margin is 33.86%, with operating and profit margins of 5.10% and 5.33%.
| Gross Margin | 33.86% |
| Operating Margin | 5.10% |
| Pretax Margin | 5.85% |
| Profit Margin | 5.33% |
| EBITDA Margin | 8.97% |
| EBIT Margin | 5.10% |
| FCF Margin | 2.43% |
Dividends & Yields
This stock pays an annual dividend of 300.00, which amounts to a dividend yield of 2.85%.
| Dividend Per Share | 300.00 |
| Dividend Yield | 2.85% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 33.69% |
| Buyback Yield | -3.86% |
| Shareholder Yield | -0.94% |
| Earnings Yield | 7.08% |
| FCF Yield | 3.22% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 14, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Apr 14, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Whan In Pharm has an Altman Z-Score of 3.96 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.96 |
| Piotroski F-Score | 3 |